<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="inhibition of coronavirus RdRp, and thus viral replication. Target-based virtual" exact="screening" post="and molecular docking results show that the antiviral Galidesivir"/>
 <result pre="SARS-CoV-2 is one of the seven coronaviruses known to cause" exact="infection" post="in Homo sapiens, which also includes: 229E (HCoV-229E), NL63"/>
 <result pre="(MLE) tree was constructed against all viral genome sequences for" exact="tracing" post="the evolutionary record with SARS-CoV-2 using a bootstrap value"/>
 <result pre="protein sequences along with SARS-CoV-2 RdRp. Ligand selection and virtual" exact="screening" post="For docking, the following ten antiviral drugs were screened:"/>
 <result pre="The pre-eminent ligand was screened against the PubChem database for" exact="detection" post="of drug-like compounds, and the Pfizer rule was applied"/>
 <result pre="see Additional file 1: Data 2 Ligand selection and virtual" exact="screening" post="All the selected ligands from a previous literature survey"/>
 <result pre="13.922) that provided us with some novel compounds in virtual" exact="screening" post="(TableÂ 3). Compounds withâ€‰&amp;gt;â€‰95% structural similarity to Galidesivir were"/>
 <result pre="withâ€‰&amp;gt;â€‰95% structural similarity to Galidesivir were selected for ligand-based virtual" exact="screening" post="from the PubChem database. A total of 1061 compounds"/>
 <result pre="found to be negative for both the compounds. Ames toxicity" exact="testing" post="results revealed that the compounds were non-toxic and non-carcinogenic"/>
 <result pre="Galidesivir etc., for which we have already tested with virtual" exact="screening" post="[67]. However, some of them are stated in TableÂ"/>
 <result pre="objective of virologists in treating the patients of new viral" exact="infection" post="caused by SARS-CoV-2. The choice of FDA approved drugs"/>
 <result pre="in clinical trials or in the market to stop viral" exact="infection" post="on an emergency basis. However, Galidesivir and its drug-like"/>
 <result pre="in China reveal bats as a reservoir for acute, self-limiting" exact="infection" post="that allows recombination eventsJ Virol2010842808281920071579 7.AhlquistPNoueiryAOLeeWMKushnerDBDyeBTHost factors in positive-strand"/>
 <result pre="M, Rajnik M, Cuomo A, et al. Features, evaluation and" exact="treatment" post="coronavirus (COVID-19) [Updated 2020 Mar 8]. In: StatPearls [Internet]."/>
 <result pre="of Past human coronavirus outbreaksPathogens.20209186 13.NguyenTMZhangYPandolfiPPVirus against virus: a potential" exact="treatment" post="for 2019-nCov (SARS-CoV-2) and other RNA virusesCell Res20203018919032071427 14.PengXXuXLiYet"/>
 <result pre="vitro. Cell Res. 2020:1-3. 22.JinYHCaiLChengZSChengHDengTFanYPFangCHuangDHuangLQHuangQHanYA rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
 <result pre="Res. 2020:1-3. 22.JinYHCaiLChengZSChengHDengTFanYPFangCHuangDHuangLQHuangQHanYA rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Military"/>
 <result pre="novel coronavirus 2019-nCoV/SARS-CoV-2Cell Discov.2020146 42.YuWCHuiDSCChan-YeungMAntiviral agents and corticosteroids in the" exact="treatment" post="of severe acute respiratory syndrome (SARS)Thorax20045964364515282381 43.ElfikyAAAnti-HCV, nucleotide inhibitors,"/>
 <result pre="anti-COVID-19 drug discovery from medicinal plantsJ Pharm Anal.202010.1016/j.jpha.2020.03.009 54.ul QamarMTMaryamAMuneerIXingFAshfaqUAKhanFAAnwarFGeesiMHKhalidRRRaufSASiddiqiARComputational" exact="screening" post="of medicinal plant phytochemicals to discover potent pan-serotype inhibitors"/>
 <result pre="protease inhibitors using pharmacophore modeling and molecular docking based virtual" exact="screening" post="of the zinc databaseInt J Pharmacol.201612621632 56.CeraoloCGiorgiFMGenomic variance of"/>
</results>
